Abstract
The business perspectives of a pharmaceutical firm (PF) are crucially affected by its portfolio of compounds under development. For this reason, companies strive to optimize the contents of their drug development pipelines. Can an “optimal portfolio” be uniquely defined? In this article, I discuss how the contents of an optimal, self-funding, pipeline can change according to the economic goal adopted by a firm. I lay out my arguments within a stylized framework, by considering three common goals for the pharmaceutical industry: increasing the market share, maximizing the expected profit, and maximizing the expected productivity. I also discuss how the optimal portfolios typically exhibit different degrees of sensitivity with respect to the relevant parameters of the models. The analysis suggests that the goal of maximizing expected productivity leads to an optimal portfolio with fewer drugs, and therefore a smaller investment in R&D as compared with the other two goals. Clinical Pharmacology & Therapeutics (2011) 89 2, 304–311. doi:10.1038/clpt.2010.247
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
